Home > Uncategorized > Empagliflozin (an inhibitor of sodium–glucose cotransporter 2) and Cardiovascular Outcomes

Empagliflozin (an inhibitor of sodium–glucose cotransporter 2) and Cardiovascular Outcomes

Empaglifozin associated with lower cardiovascular mortality despite little effect on non-fatal CV outcome in patients with type II diabetes mellitus. The paper is available here.

Advertisements
Categories: Uncategorized
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: